inozyme.com (INZY): חובות להיוון בספרים

The prospects for Inozyme Pharma, Inc. (INZY) depend on the outcomes of calcification therapy trials, while liquidity remains stable. The current leverage ratio based on balance sheet capital helps monitor the financial structure, where the latest value is recorded as 1.50. Inozyme Pharma, Inc. (INZY) is mitigating risks by covering various programs across different age groups. However, high costs associated with collecting rare data and patent protection create significant barriers to entry.

Experienced investors utilize this filter to screen out financially unstable issuers. The metric compares total liabilities to equity, determining the business's degree of dependence on borrowed funds. For Inozyme Pharma, Inc. (INZY), this balance is critical due to niche market risks and the high cost of therapy. A high debt load could accelerate the decline of shares in the event of failed trials. The current debt-to-book capitalization ratio clearly demonstrates the company's margin of safety.